LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus

A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:

• To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
• To identify the optimal length of anticoagulation in the treatment of LV Thrombus

After randomisation participants will:

• Continue their prescribed oral anticoagulant for the remainder of the trial
• Discontinue their prescribed oral anticoagulant for the remainder of the trial

Inclusion Criteria:

• Diagnosis of LV thrombus less than 12 months ago
• On Apixaban at the time of randomisation
• Completed at least 3 months of anticoagulation treatment for LV thrombus
• Persistent laminar/ mural thrombus or persistent LV dysfunction

Exclusion Criteria:

• Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement.
• SSE since LV thrombus diagnosis
• Contraindication to continuing anticoagulation therapy
• Non-ischaemic Cardiomyopathy
• Age less than 18 years
• Unable to consent